Catalyst Pharmaceuticals reports Q3 EPS 49c, two estimates 44c

Reports Q3 revenue $102.6M, two estimates $100.4M. “Our strong results in the third quarter reflect our exceptional strategic execution and substantial investment in assisting the physician community to better identify and treat LEMS patients with and without small-cell lung cancer. Our quarterly results were exceptional, having attained several significant milestones that have transformed the long-term growth trajectory of our Company,” stated Patrick J. McEnany, CEO. “We are working diligently in preparation for the commercial launch of AGAMREE(R) during the first quarter of 2024. We are pleased to be able to provide AGAMREE to the DMD community, many who have been anxiously awaiting the availability of a steroid with a favorable safety profile. Our highly skilled and experienced neuromuscular commercial and medical affairs teams will be ready to hit the ground running for the commercial launch of AGAMREE. As we look ahead to the coming year, we are confident in our ability to execute our strategic plans, laying the foundation for continued growth and sustained progress.”